236 related articles for article (PubMed ID: 28615517)
21. Unravelling the Mechanistic Role of Quinazolinone Pharmacophore in the Inhibitory Activity of Bis-quinazolinone Derivative on Tankyrase-1 in the Treatment of Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC): A Computational Approach.
Okunlola FO; Akawa OB; Subair TI; Omolabi KF; Soliman MES
Cell Biochem Biophys; 2022 Mar; 80(1):1-10. PubMed ID: 34453681
[TBL] [Abstract][Full Text] [Related]
22. Tankyrase inhibition sensitizes cells to CDK4 blockade.
Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE
PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587
[TBL] [Abstract][Full Text] [Related]
23. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
[TBL] [Abstract][Full Text] [Related]
24. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
[TBL] [Abstract][Full Text] [Related]
26. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
[TBL] [Abstract][Full Text] [Related]
27. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
[TBL] [Abstract][Full Text] [Related]
28. Tankyrase is necessary for canonical Wnt signaling during kidney development.
Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ
Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720
[TBL] [Abstract][Full Text] [Related]
29. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
Yakkala PA; Naaz F; Shafi S; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
[TBL] [Abstract][Full Text] [Related]
31. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
Luo F; Li J; Liu J; Liu K
Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
[TBL] [Abstract][Full Text] [Related]
32. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
33. Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.
Zhong Y; Katavolos P; Nguyen T; Lau T; Boggs J; Sambrone A; Kan D; Merchant M; Harstad E; Diaz D; Costa M; Schutten M
Toxicol Pathol; 2016 Feb; 44(2):267-78. PubMed ID: 26692561
[TBL] [Abstract][Full Text] [Related]
34. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
[TBL] [Abstract][Full Text] [Related]
36. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
[TBL] [Abstract][Full Text] [Related]
37. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
38. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling.
James RG; Davidson KC; Bosch KA; Biechele TL; Robin NC; Taylor RJ; Major MB; Camp ND; Fowler K; Martins TJ; Moon RT
PLoS One; 2012; 7(12):e50457. PubMed ID: 23227175
[TBL] [Abstract][Full Text] [Related]
39. Tankyrase inhibition aggravates kidney injury in the absence of CD2AP.
Kuusela S; Wang H; Wasik AA; Suleiman H; Lehtonen S
Cell Death Dis; 2016 Jul; 7(7):e2302. PubMed ID: 27441654
[TBL] [Abstract][Full Text] [Related]
40. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
